Calderasib

Calderasib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Colon Adenocarcinoma、Rectal Adenocarcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Calderasib 研究

• A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

  II 期招募中美国澳大利亚加拿大ChileNCT07209111

• A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  III 期招募中美国Argentina澳大利亚BrazilNCT07554339

• A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  III 期招募中美国Argentina澳大利亚奥地利NCT07190248

• A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  III 期招募中美国Argentina澳大利亚BrazilNCT06997497

• MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  III 期招募中Argentina澳大利亚Brazil加拿大NCT07431827

• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  III 期招募中美国Argentina澳大利亚奥地利NCT06345729

• A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

  I 期招募中美国Argentina澳大利亚加拿大NCT05067283

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。